LGL GROUP INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LGL GROUP INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.22M | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | $1.11M | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | $924.0K | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | $918.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.16M | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | $1.18M | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | $1.07M | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | $888.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $995.0K | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $978.0K | Mar 31, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $803.0K | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | $661.0K | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | $491.0K | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | $498.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $653.0K | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | $650.0K | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | $531.0K | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | $392.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $446.0K | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $438.0K | Mar 31, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.0K) | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | $772.0K | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | ($51.0K) | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | ($6.0K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $202.0K | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | $72.0K | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | $137.0K | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | $21.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $134.0K | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $108.0K | Mar 31, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $249.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $699.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $646.0K | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | ($192.0K) | Apr 17, 2023 |
| FY2022 | Sep 30, 2022 | ($528.0K) | Apr 17, 2023 |
| FY2022 | Jun 30, 2022 | ($480.0K) | Apr 17, 2023 |
| FY2022 | Mar 31, 2022 | ($847.0K) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($919.0K) | Apr 17, 2023 |
| FY2022 | Sep 30, 2021 | ($1.73M) | Apr 17, 2023 |
| FY2022 | Jun 30, 2021 | ($343.0K) | Apr 17, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.21M | Mar 28, 2022 |
| FY2021 | Dec 31, 2020 | $2.14M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.00M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.95M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.83M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $1.91M | Mar 22, 2018 |
| FY2016 | Dec 31, 2015 | $1.96M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $2.17M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $2.29M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $2.01M | Mar 31, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $874.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $385.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($817.0K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.35M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.19M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.67M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.66M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $681.0K | Mar 21, 2019 |
| FY2013 | Dec 31, 2013 | ($664.0K) | Mar 31, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $662.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.10M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $407.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.16M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $324.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $131.0K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $172.0K | Mar 22, 2018 |
| FY2016 | Dec 31, 2015 | $422.0K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $263.0K | Mar 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.78M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $43.15M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $41.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $39.79M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $60.31M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $43.46M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $39.22M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $30.08M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $27.56M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $16.65M | Mar 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.91M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.30M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.57M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.69M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $4.32M | Mar 29, 2021 |
| FY2013 | Dec 31, 2013 | $4.51M | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $4.98M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $6.83M | Apr 1, 2013 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.49M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $39.23M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $38.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $38.49M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $54.74M | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | $39.77M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $34.89M | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $27.32M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $24.93M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $13.89M | Mar 21, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $40.0K | Mar 28, 2022 |
| FY2021 | Dec 31, 2020 | $40.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $40.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $40.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $40.0K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $40.0K | Mar 22, 2018 |
| FY2016 | Dec 31, 2015 | $40.0K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $40.0K | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $40.0K | Mar 31, 2015 |
| FY2012 | Dec 31, 2012 | $40.0K | Apr 1, 2013 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.94M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($6.63M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($7.06M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.33M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.45M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($5.19M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($6.15M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($13.17M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($14.61M) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | ($14.73M) | Mar 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.51M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $41.59M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $40.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.51M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $26.38M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $18.33M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $12.45M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $15.51M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $13.25M | Mar 21, 2019 |
| FY2018 | Dec 31, 2016 | $2.78M | Mar 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 31, 2014 |
| FY2012 | Dec 31, 2012 | $58.0K | Apr 1, 2013 |
| FY2012 | Dec 31, 2011 | $400.0K | Apr 1, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.17M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 5.37M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 5.37M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 5.35M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 5.31M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 5.27M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 4.93M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 4.83M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 4.69M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | 2.68M | Mar 22, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2017 | $6.0K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $62.0K | Mar 22, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 29, 2017 |